A Phase II Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma

被引：0
|
作者：
Rosenthal, Allison C. [1 ]
Dueck, Amylou Constance [1 ]
Gano, Katherine [1 ]
Nichols, Craig [2 ]
Johnson, Daniel [1 ]
Toro, Angela [1 ]
Reddy, Sravan Nagi [1 ]
Slack, James L. [1 ]
Leis, Jose F. [1 ]
Northfelt, Donald W. [1 ]
Bergsagel, P. Leif [2 ]
Tiedemann, Rodger [3 ]
Johnston, Patrick B. [2 ]
Habermann, Thomas M. [2 ]
Witzig, Thomas E. [2 ]
Reeder, Craig B. [1 ]
机构：
[1] Mayo Clin Arizona, Scottsdale, AZ USA
[2] Mayo Clin, Rochester, MN USA
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.4748.4748
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase II Trial of Lenalidomide - Dexamethasone - Rituximab in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab.
    Ahmadi, Tahamtan
    Chong, Elise A.
    Gordon, Amanda
    Aqui, Nicole A.
    Downs, Lisa H.
    Leinbach, Leah
    Goldstein, Steven C.
    Nasta, Sunita D.
    Janofsky, Stephen
    Maniar, Tapan N.
    Svoboda, Jakub
    Schuster, Stephen J.
    BLOOD, 2009, 114 (22) : 677 - 677
  • [22] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    Fisher, Richard I.
    Bernstein, Steven H.
    Kahl, Brad S.
    Djulbegovic, Benjamin
    Robertson, Michael J.
    de Vos, Sven
    Epner, Elliot
    Krishnan, Amrita
    Leonard, John P.
    Lonial, Sagar
    Stadtmauer, Edward A.
    O'Connor, Owen A.
    Shi, Hongliang
    Boral, Anthony L.
    Goy, Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4867 - 4874
  • [23] Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Michael
    Zhang, Liang
    Fayad, Luis
    Hagemeister, Fredrick
    Neelapu, Sattva
    Samaniego, Felipe
    Pro, Barbara
    Younes, Anas
    Miller, Scott
    Knight, Robert D.
    Zeldis, Jerome B.
    Yi, Qing
    Romaguera, Jorge
    BLOOD, 2008, 112 (11) : 1051 - 1051
  • [24] Rituximab and High-Dose Cytarabine/Dexamethasone (R-HAD) Plus Bortezomib Is Superior to R-HAD Only in Relapsed Mantle Cell Lymphoma: A Randomized Phase 3 Trial of the European MCL Network
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 13 - 14
  • [25] Phase II study of high dose outpatient cyclophosphamide and rituximab, without stem cell support, for low grade and mantle cell
    Swinnen, Lode J.
    Jones, Richard J.
    Jung, Miah
    Flinn, Ian W.
    BLOOD, 2006, 108 (11) : 775A - 776A
  • [26] Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trial
    Furtado, Michelle
    Dyer, Martin J. S.
    Johnson, Rod
    Berrow, Margie
    Rule, Simon
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (04) : 575 - 578
  • [27] Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
    Hess, Georg
    Wagner, Karola
    Keller, Ulrich
    La Rosee, Paul
    Atta, Johannes
    Huebel, Kai
    Lerchenmueller, Christian
    Schoendube, Daniel
    Witzens-Harig, Mathias
    Ruckes, Christian
    Medler, Christoph
    van Oordt, Christina
    Klapper, Wolfram
    Theobald, Matthias
    Dreyling, Martin
    HEMASPHERE, 2020, 4 (03):
  • [28] A randomised phase II study of fludarabine/cyclophosphamide +/-rituximab in patients with untreated mantle cell lymphoma
    Rule, S
    Burton, C
    Waleski, J
    Jack, A
    Seymour, J
    ANNALS OF ONCOLOGY, 2005, 16 : 95 - 95
  • [29] Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
    Wang, Michael
    Fayad, Luis
    Wagner-Bartak, Nicolaus
    Zhang, Liang
    Hagemeister, Fredrick
    Neelapu, Sattva S.
    Samaniego, Felipe
    McLaughlin, Peter
    Fanale, Michelle
    Younes, Anas
    Cabanillas, Fernando
    Fowler, Nathan
    Newberry, Kate J.
    Sun, Luhong
    Young, Ken H.
    Champlin, Richard
    Kwak, Larry
    Feng, Lei
    Badillo, Maria
    Bejarano, Maria
    Hartig, Kimberly
    Chen, Wendy
    Chen, Yiming
    Byrne, Catriona
    Bell, Neda
    Zeldis, Jerome
    Romaguera, Jorge
    LANCET ONCOLOGY, 2012, 13 (07): : 716 - 723
  • [30] A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Luhua
    Fayad, Luis
    Hagemeister, Fredrick B.
    Neelapu, Sattva
    Samaniego, Felipe
    McLaughlin, Peter
    Samuels, Barry
    Yi, Qing
    Pro, Barbara
    Fanale, Michelle
    Shah, Jatin
    Younes, Anas
    Bell, Neda
    Knight, Robert
    Zeldis, Jerome B.
    Cabanillas, Fernando
    Kwak, Larry
    Romaguera, Jorge
    BLOOD, 2009, 114 (22) : 1064 - 1065
12345